TORONTO, Nov. 23, 2016 /CNW/ - Syncordia Technologies
and Healthcare Solutions, Corp. (TSXV: SYN) ("Syncordia" or the
"Company") today reported financial results for the three and six
months ended September 30, 2016.
Reported results reflect six months of operations of Health
Services Integration Inc. ("HSI"), which was acquired effective
October 31, 2014, Paragon Billing
LLC, ("Paragon") which was acquired April
24, 2015, and Billing Solutions LLC ("Billing Solutions"),
which was acquired March 22, 2016.
All results are reported in thousands of US dollars and are
prepared in accordance with International Financial Reporting
Standards ("IFRS").
Management Commentary
Along with the Company's refinancing efforts, Syncordia
continues to evaluate various strategic alternatives including, but
not limited to, the divestiture of a portfolio company to reduce
debt and put additional cash on the balance sheet, along with the
idea of a business combination or merger of equals involving one of
Syncordia's portfolio companies, and other M&A activity in
exchange for a minority position/software licensure and management
contract agreement(s) in the target. The Company believes these
steps will unlock the value that exists in the enterprise and allow
Syncordia to expand further in the RCM space.
Michael Franks, Chief Executive
Officer, said "to ensure sufficient working capital to capitalize
on new contract growth, Syncordia signed a waiver with its lending
group to short pay the scheduled principal payment by $875 thousand, representing 39% of the scheduled
amount. We view this as a positive event in our corporate timeline
as the lending group realizes the true value of the enterprise and
showed their willingness to be supportive of Syncordia's efforts,
its mission and strategic plan.
We would like to thank the lenders for their ongoing support and
will continue our refinancing efforts and operational initiatives
to drive free cash flow for the benefit of lenders and
shareholders. Our cost per ground claim continues to drop from an
average of $25/claim last quarter to
$21/claim in Q2 to around
$18 now. Historically in another
business we have managed cost per claim of approximately
$10 for ground claims and this is the
direction we are headed. Air cost per claim was $114/claim in Q1 and has dropped to $84/claim in Q2. We are taking steps now to
reduce this further. We also continue to reduce headcounts
and rationalize costs in our Corporate offices, and have
streamlined Platform Syncordia."
Business Highlights
- Obtained a waiver from senior lending consortium, resulting in
reduced principal payment of $1.35
million in November 2016
instead of $2.22 million in order to
maintain adequate flexibility and liquidity for working capital
needs. The shortfall of $0.88 million
will be added to the May 2017
principal repayment.
- The Company is pursuing a number of alternatives with regard to
refinancing our senior debt.
- Management is exploring strategic alternatives, including but
not limited to (i) the sale of portfolio RCM company or companies
(ii) strategic alliances with HSI to improve overall results (iii)
licensing or sale of certain intellectual property (iv) other
cash-generating initiatives. Syncordia maintains three operating
businesses that we anticipate could be sold at favorable multiples
and would maximize value as Platform Syncordia and Corporate costs
would not be required by the new owners in the event of a sale.
- Billing Solutions entered into several new contracts for
billing services subsequent to the first quarter, expected to
represent approximately 50,000 annual treatment encounters.
- Paragon is anticipated to sign a customer contract with
expected volume of 50,000 annual encounters. This contract would
represent an increase in Paragon's encounters by approximately 20%,
and is expected to begin in January
2017.
- Syncordia is introducing Claim Editor and additional staff in
its Maryland billing center to
further reduce cost per claim.
- Announced NECTAR, a client analytics portal for our behavioural
health customers, consisting of a business intelligence dashboard
showing key medical practice performance indicators.
- Announced Coordinet, a proprietary cloud-based application
designed to assist hospital systems in the coordination of care for
high risk patients with the goal of minimizing inappropriate
readmissions and the resulting fines from Centers for Medicare and
Medicaid.
- Announced TransferLink, a web based client portal for
department managers and hospital administrators to track and manage
patient transfer information, including real time operational
dashboards with analytics depicting HIPAA compliant displays.
Second Quarter 2017 Compared to Second Quarter 2016
- Revenue decreased $275 or 7%,
$1,340 of which is attributable to
REACH Air Medical Holdings and affiliated entities as we wind down
the provision of billing services to this customer group as well as
other payor mix changes at HSI, offset by $1,513 which was attributable to the acquisition
of Billing Solutions.
- Gross margin decreased from 72% to 58% of revenue primarily
reflecting a lower portion of our revenue from higher margin air
transports.
- Adjusted EBITDA before Platform Syncordia and Corporate costs
decreased $950 or 55% primarily
reflecting lower revenues at HSI.
- Platform Syncordia costs were relatively unchanged, reflecting
our software development efforts as we continue to develop the
Syncordia Billing Module.
- Corporate costs decreased $97 or
15% reflecting several cost reduction initiatives.
- Adjusted EBITDA was negative $176, before accounting for non-controlling
interests.
- Cash and cash equivalents of $2,974.
Second Quarter 2017 Financial Highlights
- Revenue was $3,624 and is
segmented by RCM business as follows - $1,652 HSI, $459
Paragon and $1,513 Billing
Solutions
- Adjusted EBITDA was negative $307, reflecting our 80% interest in Billing
Solutions.
- Cash and cash equivalents of $2,974.
Key Performance Indicators
We report Encounters as a
key performance indicator to assist readers in better evaluating
our performance. We define an Encounter as a discrete business
activity for which we would submit a claim. We believe this metric
provides investors with a better proxy for measuring the level of
business activity than revenue as encounters measure the number of
distinct services provided in the period whereas revenue reflects
the amount of services recognized for accounting purposes and is
typically a lagging indicator of business activity.
|
Encounters
|
Sequential
Quarterly Change
|
|
|
|
Quarter
|
Q1
FY2017
|
Q2
FY2017
|
YTD
FY2017
|
#
|
%
|
Air/SCT
|
2,744
|
3,903
|
6,647
|
1,159
|
42%
|
Ground
|
7,202
|
12,231
|
19,433
|
5,029
|
70%
|
HSI
|
9,946
|
16,134
|
26,080
|
6,188
|
62%
|
Paragon
|
82,430
|
63,809
|
146,239
|
(18,621)
|
(23%)
|
Billing
Solutions
|
46,697
|
48,052
|
94,749
|
1,355
|
3%
|
HSI encounters increased 62% reflecting the on-boarding of Mercy
Health North LLC and LACP/St. Rita's Medical Center. Specialty Care
Transport (SCT) encounters were 245 and 901 in the first and second
quarter, respectively. Paragon encounters decreased 18,621 or 23%
due to seasonality and customer churn. Billing Solutions encounters
increased 3% primarily as a result of new customers.
Notice of Conference Call
Syncordia will hold a
conference call on Thursday, November 24,
2016, at 8:00 a.m (ET) to discuss its financial results and
other corporate developments. To access the conference call by
telephone, dial 647-427-7450 or 1-888-231-8191. A live audio
webcast will be available through www.syncordiahealth.com or
http://event.on24.com/r.htm?e=1309987&s=1&k=924601BCAA1A9D2932324974BAA379A5
.An archived replay of the webcast will be available for 90 days. A
presentation will accompany the conference call and will be
available for download from the Investor Relations section of
Syncordia's website at:
http://www.syncordiahealth.com/company/investor-relations/events-presentations/.
Forward Looking Statements
Certain statements herein
may be "forward looking" statements that involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, performance or achievements of Syncordia or the industry
to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Forward looking statements involve significant risks
and uncertainties, should not be read as guarantees of future
performance or results, and will not necessarily be accurate
indications of whether or not such results will be achieved. A
number of factors could cause actual results to vary significantly
from the results discussed in the forward looking statements. These
forward looking statements reflect current assumptions and
expectations regarding future events and operating performance and
are made as of the date hereof and we assume no obligation, except
as required by law, to update any forward looking statements to
reflect new events or circumstances.
Cautionary Note Regarding Non-IFRS Measures
This press
release contains references to "EBITDA," "Adjusted EBITDA," "Gross
margin," and "Adjusted EBITDA before Platform Syncordia and
Corporate costs."
Earnings before Interest, Taxes, Depreciation and Amortization
("EBITDA") and Adjusted Earnings before Interest, Taxes,
Depreciation and Amortization ("Adjusted EBITDA") are non-IFRS
measures used by management to provide additional insight into our
performance and financial condition. We believe that these
non-IFRS measures are important as they provide an indication of
the results generated by our RCM business prior to taking into
consideration how those activities are financed as well as the
other items listed in their respective definitions.
Accordingly, we are presenting EBITDA, Adjusted EBITDA and Adjusted
EBITDA before Platform Syncordia and Corporate costs in this
MD&A to enhance the usefulness of our MD&A. We have
provided below a reconciliation of EBITDA, Adjusted EBITDA and
Adjusted EBITDA before Platform Syncordia Corporate costs to the
most directly comparable IFRS figures, disclosure of the purpose of
the non-IFRS measure, and how the non-IFRS measures is used in
managing the business.
EBITDA, Adjusted EBITDA and Adjusted EBITDA before Platform
Syncordia and Corporate costs are not calculations based on IFRS
and should not be considered an alternative to operating income or
net income (loss) in measuring the our performance, nor should it
be used as an exclusive measure of cash flow, because it does not
consider the impact of working capital growth, capital
expenditures, debt principal reductions and other sources and uses
of cash which are disclosed in the consolidated statements of cash
flows. Investors should carefully consider the specific items
included in our computation of these measures.
Management defines EBITDA as Earnings before Interest, Taxes,
Depreciation and Amortization.
Management defines Adjusted EBITDA as Earnings before Interest,
Taxes, Depreciation, Amortization, Transaction Costs, Fair Value
Gains/Losses, Foreign Exchange Gains/Losses, Stock Based
Compensation and Cash based Share Compensation Arrangements.
Transaction costs include professional fees associated with
business transactions.
Management defines Adjusted EBITDA before Platform Syncordia and
Corporate costs as Earnings before Interest, Taxes, Depreciation,
Amortization, Transaction Costs, Fair Value Gains/Losses, Foreign
Exchange Gains/Losses, Stock Based Compensation, Cash based Share
Compensation Arrangements and costs of our Platform Syncordia and
Corporate segment. This metric is used to assess the performance of
RCM and Platform Syncordia segments.
Gross margin is a non-IFRS measure defined by management to
reflect revenue less direct cost of sale, excluding amortization of
intellectual property, customer lists, other amortizations and fair
value gains/losses.
Platform Syncordia and Corporate costs include sales and
marketing, general and administrative and research and development,
less amortization and depreciation, foreign exchange gains and
losses, and stock-based compensation expense indexed to our share
price.
About Syncordia Technologies and Healthcare Solutions,
Corp.
We are a technology enhanced revenue cycle management
("RCM") company focused on underserved niche segments of the
healthcare industry. We are building a diversified software and
services business by consolidating healthcare billing providers.
Our growth strategy is to acquire RCM businesses with and without
software and, improve their profitability by increasing revenues
and operating efficiencies using our software, and in time,
commercializing Platform Syncordia, our cloud-based software
offering, to provide customer demanded turn-key solutions from a
single provider and to address compelling RCM market
opportunities.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
The following is a reconciliation of EBITDA with net loss and
comprehensive loss:
(in thousands of US Dollars)
|
|
|
|
|
Three Months
ended
|
Three Months
ended
|
Six Months
ended
|
|
Sep
30
2016
|
Sep
30
2015
|
Sep
30
2016
|
Jun
30
2016
|
Sep
30
2016
|
Sep
30
2015
|
|
|
|
|
|
|
|
Net loss and
comprehensive loss
|
(1,594)
|
(138)
|
(1,594)
|
(1,576)
|
(3,170)
|
(1328)
|
Amortization of
operating and other assets
|
939
|
772
|
939
|
930
|
1,869
|
1,501
|
Income tax expense
(recovery)
|
(60)
|
-
|
(60)
|
(28)
|
(88)
|
-
|
Interest
expense
|
530
|
476
|
530
|
523
|
1,053
|
920
|
EBITDA
|
(185)
|
1,110
|
(185)
|
(151)
|
(336)
|
1,093
|
The following is a reconciliation of Adjusted EBITDA and
Adjusted EBITDA before Platform Syncordia and Corporate costs with
Net loss and comprehensive loss:
(in thousands of US Dollars)
|
|
|
|
|
Three Months
ended
|
Three Months
ended
|
Six Months
ended
|
|
Sep
30
2016
|
Sep
30
2015
|
Sep
30
2016
|
Jun
30
2016
|
Sep
30
2016
|
Sep
30
2015
|
|
|
|
|
|
|
|
Net loss and
comprehensive loss
|
(1,594)
|
(138)
|
(1,594)
|
(1,576)
|
(3,170)
|
(1,328)
|
Amortization of
operating and other assets
|
939
|
772
|
939
|
930
|
1,869
|
1,501
|
Income tax expense
(recovery)
|
(60)
|
-
|
(60)
|
(28)
|
(88)
|
-
|
Interest
expense
|
530
|
476
|
530
|
523
|
1,053
|
920
|
Transaction
costs
|
-
|
47
|
-
|
1
|
1
|
1,769
|
Foreign exchange
(gains) and losses
|
-
|
106
|
-
|
3
|
3
|
134
|
Unrealized (gains)
and losses on derivative
financial liability
|
-
|
(608)
|
-
|
-
|
-
|
(608)
|
Realized gain on
contingent consideration
|
-
|
-
|
-
|
-
|
-
|
(1,111)
|
Stock based
compensation
|
9
|
21
|
9
|
11
|
20
|
50
|
Adjusted EBITDA
(i)
|
(176)
|
676
|
(176)
|
(136)
|
(312)
|
1,327
|
Platform Syncordia
costs (i)
|
393
|
394
|
393
|
487
|
880
|
694
|
Corporate costs
(i)
|
546
|
643
|
546
|
485
|
1,031
|
1,254
|
Adjusted EBITDA
before Platform Syncordia
and Corporate costs (i)
|
763
|
1,713
|
763
|
836
|
1,599
|
3,275
|
|
Notes:
|
(i)
|
Non-IFRS measure,
Platform Syncordia and Corporate costs exclude stock based
compensation, transaction costs, foreign exchange gains and loss,
fair value adjustments, and amortization.
|
Syncordia
Technologies and Healthcare Solutions, Corp.
|
Condensed Interim
Consolidated Statements of Financial Position
|
As at September 30,
2016 and March 31, 2016
|
|
|
|
|
|
|
September
30
2016
|
March
31
2016
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
Current
assets
|
|
|
|
|
Cash and cash
equivalents
|
|
2,974,012
|
4,436,844
|
|
Accounts
receivable
|
|
2,342,462
|
2,226,715
|
|
Other
assets
|
|
236,414
|
377,185
|
|
|
|
|
|
|
5,552,888
|
7,040,744
|
|
|
|
|
Property and
equipment
|
|
349,218
|
338,622
|
|
|
|
|
Intangible
assets
|
|
21,046,342
|
22,694,613
|
|
|
|
|
Goodwill
|
|
10,758,996
|
10,781,769
|
|
|
|
|
|
|
37,707,444
|
40,855,748
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
Accounts payable and
accrued liabilities
|
|
1,426,338
|
1,584,735
|
|
Holdback
payable
|
|
-
|
250,000
|
|
Current portion of
notes payable
|
|
4,444,129
|
2,222,065
|
|
|
|
|
|
|
5,870,467
|
4,056,800
|
|
|
|
|
Notes
payable
|
|
10,596,957
|
12,350,631
|
|
|
|
|
Deferred tax
liabilities
|
|
1,806,143
|
1,932,097
|
|
|
|
|
Other non-current
liabilities
|
|
225,747
|
133,076
|
|
|
|
|
|
|
18,499,314
|
18,472,604
|
|
|
|
|
Shareholders'
Equity
|
|
|
|
|
|
|
|
Share
capital
|
|
25,529,338
|
25,517,330
|
|
|
|
|
Contributed
surplus
|
|
1,986,203
|
1,963,529
|
|
|
|
|
Deficit
|
|
(9,317,730)
|
(6,010,506)
|
|
Equity attributable
to shareholders of Syncordia
|
|
18,197,811
|
21,470,353
|
|
Non-controlling
interests
|
|
1,010,319
|
912,791
|
|
|
19,208,130
|
22,383,144
|
|
|
|
|
|
|
37,707,444
|
40,855,748
|
Syncordia
Technologies and Healthcare Solutions, Corp.
|
Condensed Interim
Consolidated Statements of Loss and Comprehensive Loss
|
For the three and six
months ended September 30, 2016 and 2015
|
|
|
|
|
Three months
ended
September
30
|
Six months
ended
September
30
|
|
2016
|
2015
|
2016
|
2015
|
|
|
|
|
|
Revenue
|
3,624,604
|
3,898,903
|
7,734,186
|
7,291,698
|
|
|
|
|
|
Gain on settlement
of contingent consideration
|
-
|
-
|
-
|
1,111,342
|
|
3,624,604
|
3,898,903
|
7,734,186
|
8,403,040
|
|
|
|
|
|
Cost of
sales
|
1,518,859
|
1,079,434
|
3,200,079
|
2,092,166
|
|
|
|
|
|
Amortization of
operating assets
|
855,731
|
704,652
|
1,700,641
|
1,368,983
|
|
1,250,014
|
2,114,817
|
2,833,466
|
4,941,891
|
|
|
|
|
|
Operating
expenses
|
2,290,820
|
2,270,264
|
4,869,759
|
4,056,187
|
|
|
|
|
|
Transaction
costs
|
-
|
47,378
|
916
|
1,769,428
|
|
|
|
|
|
Other
amortization
|
82,979
|
66,986
|
168,136
|
132,286
|
Loss before
financing and tax expenses
|
(1,123,785)
|
(269,811)
|
(2,205,345)
|
(1,016,010)
|
|
|
|
|
|
Change in fair
value of derivative financial liability
|
-
|
(607,961)
|
-
|
(607,961)
|
|
|
|
|
|
Interest
expense
|
530,131
|
475,757
|
1,052,799
|
919,643
|
|
|
|
|
|
Net loss before
tax
|
(1,653,916)
|
(137,607)
|
(3,258,144)
|
(1,327,692)
|
|
|
|
|
|
Income tax expense
(recovery)
|
(60,024)
|
-
|
(88,448)
|
-
|
|
|
|
|
|
Net loss and
comprehensive loss for the period
|
(1,593,892)
|
(137,607)
|
(3,169,696)
|
(1,327,692)
|
|
|
|
|
|
Net loss and
comprehensive loss attributable to:
|
|
|
|
|
|
Shareholders of
Syncordia
|
(1,705,585)
|
(137,607)
|
(3,307,224)
|
(1,327,692)
|
|
Non-controlling
interests
|
111,693
|
-
|
137,528
|
-
|
|
|
|
|
|
Net loss per
share
|
|
|
|
|
|
Basic and diluted
earnings per share
|
(0.09)
|
(0.01)
|
(0.17)
|
(0.08)
|
|
|
|
|
|
Weighted average
number of shares outstanding
|
|
|
|
|
|
Basic
|
19,650,564
|
19,643,635
|
16,647,119
|
17,610,993
|
|
Diluted
|
19,650,564
|
19,799,804
|
16,647,119
|
17,767,162
|
Syncordia
Technologies and Healthcare Solutions, Corp.
|
Condensed Interim
Consolidated Statements of Cash Flows
|
For the three and six
month periods ended September 30, 2016 and 2015
|
|
|
|
|
Three months
ended
September
30
|
Six months
ended
September
30
|
|
2016
|
2015
|
2016
|
2015
|
|
|
|
|
|
Cash provided by
(used in)
|
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
|
|
|
Net loss for the
period
|
(1,593,892)
|
(137,607)
|
(3,169,696)
|
(1,327,692)
|
Items not affecting
cash
|
|
|
|
|
|
Gain on settlement of
contingent consideration
|
-
|
-
|
-
|
(1,111,342)
|
|
Reverse Takeover
transaction costs
|
-
|
-
|
-
|
1,068,920
|
|
Income tax expense
(recovery)
|
(60,023)
|
-
|
(125,954)
|
-
|
|
(Gain)/loss on
derivative liability
|
-
|
(607,961)
|
-
|
(607,961)
|
|
Amortization
|
938,710
|
771,638
|
1,868,777
|
1,501,269
|
|
Non-cash interest on
notes payable
|
218,054
|
171,129
|
433,218
|
328,888
|
|
Share-based
compensation and awards
|
9,603
|
20,294
|
20,136
|
50,008
|
Changes in non-cash
working capital items
|
|
|
|
|
|
Accounts
receivable
|
(92,020)
|
224,954
|
(115,746)
|
83,564
|
|
Other
assets
|
21,887
|
12,343
|
140,770
|
(72,062)
|
|
Accounts payable and
accrued liabilities
|
(52,704)
|
(434,854)
|
(145,285)
|
(64,021)
|
|
Other non-current
liabilities
|
1,031
|
43,590
|
2,242
|
83,839
|
|
(609,354)
|
64,156
|
(1,091,538)
|
(66,590)
|
|
|
|
|
|
Investing
activities
|
|
|
|
|
|
|
|
|
|
Purchase of property,
equipment and intangible assets
|
(82,783)
|
(54,856)
|
(104,067)
|
(123,530)
|
Working capital
settlement for acquisition of Billing Solutions
|
22,773
|
-
|
22,773
|
-
|
Acquisition of
Paragon (net of cash acquired)
|
-
|
-
|
-
|
(3,479,929
|
Settlement of Paragon
holdback
|
-
|
(250,000)
|
(250,000)
|
(250,000)
|
Settlement of
contingent consideration
|
-
|
-
|
-
|
(1,208,658)
|
|
(60,010)
|
(304,856)
|
(331,294)
|
(5,062,117)
|
|
|
|
|
|
Financing
activities
|
|
|
|
|
Issuance of Class B
Series 2 preferred shares
|
-
|
-
|
-
|
3,405,000
|
Issuance of private
placement
|
-
|
-
|
-
|
8,052,460
|
Cash consideration
from issuance of Reverse Takeover shares
|
-
|
-
|
-
|
402,605
|
Share issuance
costs
|
-
|
(920)
|
-
|
(831,560)
|
Proceeds from
long-term notes
|
-
|
-
|
-
|
1,332,388
|
Deferred financing
costs
|
-
|
-
|
-
|
(29,960)
|
Distributions to
non-controlling interest
|
(20,000)
|
-
|
(40,000)
|
-
|
|
(20,000)
|
(920)
|
(40,000)
|
12,330,933
|
|
|
|
|
|
Increase/(decrease)
in cash and cash equivalents during the period
|
(689,364)
|
(241,620)
|
(1,462,832)
|
7,202,226
|
|
|
|
|
|
Cash and cash
equivalents - Beginning of period
|
3,663,376
|
10,286,259
|
4,436,844
|
2,842,413
|
Cash and cash
equivalents - End of period
|
2,974,012
|
10,044,639
|
2,974,012
|
10,044,639
|
|
|
|
|
|
Cash interest
paid
|
312,259
|
306,073
|
619,590
|
592,200
|
|
|
|
|
|
SOURCE Syncordia Technologies and Healthcare Solutions,
Corp.